What is NGM Biopharmaceuticals, Inc. (NGM)?

NGM Biopharmaceuticals, Inc. (NGM) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of NGM?

The current price of NGM is $1.54. Prices are updated in real time on Stocks360.

What is NGM's price-to-earnings (PE) ratio?

NGM's trailing twelve-month PE ratio is -0.89, based on current price and earnings per share data available on Stocks360.

What is NGM's market capitalization?

NGM's market capitalization is $128,532,096.00, placing it in the small-cap tier.

NGM Biopharmaceuticals, Inc. (NGM)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$1.54

Market Cap

$128.53M

PE (TTM)

-0.89

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.26

Day Range

$1.54 – $1.57

52-wk Range

$0.60 – $4.69

Avg Volume

N/A

Volume

2.21M

NGM Biopharmaceuticals, Inc. (NGM) is a publicly traded company in the Healthcare sector. Latest price: $1.54. Market cap $128.53M. Trailing PE -0.89. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

May 2, 2024

EPS $-0.58 vs est. $-0.46

Missed by $0.12

Proprietary Signals

Signal snapshot temporarily unavailable.

About NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, an…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.89×
P/S (TTM)	29.10×
P/B	0.85×
P/FCF (TTM)	-0.96×
EV / EBITDA	-0.48×
EV / Sales	15.78×
Earnings Yield	-112.07%
Free Cash Flow Yield	-103.83%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$69.72M
Revenue (TTM)	$4.42M
Net Income (TTM)	-$144.04M
Free Cash Flow (TTM)	-$133.45M
Net Debt	-$58.81M
Working Capital	$136.36M
Gross Margin	49.72%
Operating Margin	-3317.79%
Net Margin	-3223.34%
Return on Equity	-69.76%
Return on Invested Capital	-98.49%